Cargando…
Adding erythropoietin to intravenous methylprednisolone in acute treatment of attacks of neuromyelitis optica spectrum disorders: A randomized controlled trial
Background: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system (CNS) that prompts immediate potent treatment. Delaying treatment could leave debilitating sequelae. As erythropoietin (EPO) has shown neuroprotective effects, we studied the effects of...
Autores principales: | Shafaei, Maryam, Ghadiri, Fereshteh, Azimi, Amirreza, Moghadasi, Abdorreza Naser, Hakiminezhad, Mahdi, Sahraian, Mohammad Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189199/ https://www.ncbi.nlm.nih.gov/pubmed/38011377 http://dx.doi.org/10.18502/cjn.v21i4.11715 |
Ejemplares similares
-
Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran
por: Sahraian, Mohammad Ali, et al.
Publicado: (2020) -
The association between body mass index, demographic and clinical characteristics with cognitive performance in patients with neuromyelitis optica spectrum disorder
por: Rezaeimanesh, Nasim, et al.
Publicado: (2022) -
Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV
por: Ali Sahraian, Mohammad, et al.
Publicado: (2021) -
The study of COVID-19 infection following vaccination in patients with multiple sclerosis
por: Ghadiri, Fereshteh, et al.
Publicado: (2022) -
The perspective of Iranian patients with multiple sclerosis on the third dose of COVID-19 vaccine
por: Ghadiri, Fereshteh, et al.
Publicado: (2022)